Tinodasertib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Explore 31 assets in B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03414450CT.gov Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tinodasertib (this asset) | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | P1 | CC · 43 |
| Nilotinib | The University of Hong Kong | P2 | BB |
| Cytarabine | Novartis Pharmaceuticals | P3 | BB |
| Blinatumomab | Novartis Pharmaceuticals | P3 | BB |
| Imatinib | The University of Hong Kong | P3 | BB |
| Methotrexate | Novartis Pharmaceuticals | P3 | BB |
| Dasatinib | SWOG Cancer Research Network | P3 | BB |
| Olverembatinib | Institute of Hematology & Blood Diseases Hospital, China | P3 | BB |
| Prednisone | University of Washington | P3 | B |
+39 more in the B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) cohort
Other indications for Tinodasertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P2 | CC · 45 |
| Acute Lymphoblastic Leukemia | — | P1 | CC · 43 |
| Leukemia, Myeloid, Accelerated-Phase | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tinodasertib in B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2). Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tinodasertib-b-lymphoblastic-leukemialymphoma-with-t922q341q112
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →